论文部分内容阅读
作者对39例骨髓增生性疾患(其中真红14例;原发性血小板增多15例;特发性骨髓纤维化9例;不能分类1例).用羟基脲治疗,开始用100 150mg/日,以后随血象调整.作者在治疗前及随访中进行骨髓活检,将骨髓中纤维化程度分为4级.在治疗6-54个月(平均18个月)的随访记录中,血小板生成的变化为:治疗前正常、轻度、中度和重度增加的例数分别为1,10,25,3;治疗后为14,19,6,0.其中27例减少,10例无变化,仅2例增加(P<0.01).纤维化的变化:患者按0,1,2,3共4级例数在治疗前分别为8,14,14,3,治疗后为17,14,6,2.纤维化程度由二位血液病理学家分别观察,结果是:纤维化减少的20例,不变的15例,增加的4例(P=0.01)作者还意外的发现在治疗后有巨核细胞异常的
The authors of 39 cases of myeloproliferative disorders (including 14 cases of true red; 15 cases of idiopathic thrombocytopenia; idiopathic myelofibrosis in 9 cases; can not be classified in 1 case.) Treatment with hydroxyurea began with 100 150mg / day, Followed by the blood to adjust the author before treatment and follow-up of bone marrow biopsy, bone marrow fibrosis degree is divided into 4 in the treatment of 6-54 months (mean 18 months) follow-up records, changes in platelet production was : Before treatment, the number of normal, mild, moderate and severe increase were 1,10,25,3 respectively; 14,19,6,0 after treatment, of which 27 cases decreased, 10 cases had no change, only 2 cases (P <0.01) .Fibrosis changes: According to 0,1,2,3 total 4 cases of patients before treatment were 8,14,14,3, 17,14,6,2 after treatment. The degree of fibrosis was observed by two hematopathologists, and the result was: 20 cases of fibrosis reduction, 15 cases of invariability and 4 cases of increase (P = 0.01). The authors also unexpectedly found that after treatment, there were abnormalities of megakaryocytes of